# PATENT ATTORNEY DOCKET NO. 50026/059001

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Iwadate et al.

Art Unit:

Not Yet Assigned

Serial No.:

10/585,884

Examiner:

Not Yet Assigned

Filed:

July 12, 2006

Customer No.:

21559

Title:

GENE THERAPY FOR TUMORS USING MINUS-STRAND RNA

VIRAL VECTORS ENCODING IMMUNOSTIMULATORY

CYTOKINES (AS AMENDED)

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SUBMISSION OF TRANSLATION OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Applicants submit herewith the Translation of the International Preliminary Report on Patentability corresponding to the above-referenced application. Applicants petition for any necessary extensions of time for submission of this document.

In addition, if there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 26 December 2006

James D. DeCamp, Ph.D.

Reg. No. 43,580

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

### From the INTERNATIONAL BUREAU

## PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)
(PCT Rules 44bis.3(c) and 72.2)

То:	
SHIMIZU, Hatsushi Kantetsu Tsukuba Bldg. 6F Oroshi-machi Tsuchiura-shi Ibaraki 3000847 JAPON	RECEIVED WITH THANKS NOV - 6, 2006 SHIMIZU PATENT OFFICE

Date of mailing (day/month/year)
26 October 2006 (26.10.2006)

Applicant's or agent's file reference D3-A0309P

IMPORTANT NOTIFICATION

International application No. PCT/JP2005/000238

International filing date (day/month/year) 12 January 2005 (12.01.2005)

Applicant

DNAVEC RESEARCH INC. et al

١.	Transmittal	of	the	translation	to	the a	pplicant

	The International Bureau transmits herewith a copy of the English translation of the international preliminary report of patentability (Chapter I).
--	---

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

### 2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

EP, KR

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Yoshiko Kuwahara

Facsimile No. +41 22 338 82 70

Facsimile No. +41 22 338 82 70

# TRANSLATION PATENT COOPERATION TREATY POT

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Form PCT/IPEA/416	
D3-A0309P			
International application No.	International filing date (day/month/year)	Priority date (day/month/year)	
PCT/JP2005/000238	12.01.2005	13.01.2004	
International Patent Classification (IPC) or nation			
A61K48/00, A61K38/00, A61P35/00, C12N5/10,		76, A61K39/00,	
Applicant			
DNAVEC RESEARCH INC.			
, i			
		his International Preliminary Examining Authority	
under Article 35 and transmitted to the			
2. This REPORT consists of a total of _	sheets, inch	ading this cover sheet.	
3. This report is also accompanied by Al	NNEXES, comprising:		
a. (sent to the applicant and	to the International Bureau) a total of	sheets, as follows:	
sheets of the descrip	tion, claims and/or drawings which have be tifications authorized by this Authority (see	en amended and are the basis for this report and/or e Rule 70.16 and Section 607 of the Administrative	
Instructions).			
		considers contain an amendment that goes beyond ated in item 4 of Box No. I and the Supplemental	
		A confederate contrates	
b (sent to the International i	Bureau only) a total of (indicate type and nu	imber of electronic carrier(s))	
		containing a sequence listing and/or tables	
Section 802 of the Administ		pplemental Box Relating to Sequence Listing (see	
4. This report contains indications relati	ng to the following items:		
Box No. I Basis of the			
Box No. II Priority			
		at a second to be at the area to 100 at 100 at	
	shment of opinion with regard to novelty, in	iventive step and industrial applicability	
	ty of invention		
Box No. V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
Box No. VI Certain doc	uments cited		
Box No. VII Certain defe	Box No. VII Certain defects in the international application		
Box No. VIII Certain obs	ervations on the international application	^	
Date of submission of the demand Date of comp		of this report	
Name and mailing address of the IPEA/JP	Authorized officer		
Facsimile No.	Telephone No.		

International application No.
PCT/JP2005/000238

Box	No. I	Basis of the report	
1.		n regard to the language, this report is based on the international a cated under this item.	application in the language in which it was filed, unless otherwise
		This report is based on translations from the original language in which is the language of a translation furnished for the purposes	
		international search (Rule 12.3 and 23.1(b))	
		publication of the international application (Rule 12.4)	-
		international preliminary examination (Rule 55.2 and/or 5	55.3)
2.	recei	n regard to the elements of the international application, this repo iving Office in response to an invitation under Article 14 are re report):	ort is based on (replacement sheets which have been furnished to the ferred to in this report as "originally filed" and are not annexed to
	$\boxtimes$	the international application as originally filed/furnished	
		the description:	•
		pages	as originally filed/furnished
		pages <sup>st</sup> re	
		pages* re	
	П	the claims:	
	I		as originally filed/furnished
		nos.	as amended (together with any statement) under Article 19
			eccived by this Authority on
		nos.** re	eccived by this Authority on
		the drawings:	
		sheets	as originally filed/furnished
			eceived by this Authority on
		sheets <sup>4t</sup> re	eceived by this Authority on
	$\boxtimes$	a sequence listing and/or any related table(s) see Supplementa	al Box Relating to Sequence Listing.
3.		The amendments have resulted in the cancellation of:	
		the description, pages	
		the claims, nos.	
		the drawings, sheets/figs	
		the sequence listing (specify):	
		any table(s) related to sequence listing (specify):	
4.		This report has been established as if (some of) the amendme they have been considered to go beyond the disclosure as filed	ents annexed to this report and listed below had not been made, since, as indicated in the Supplemental Box (Rule 70.2(c)).
		the description, pages	
		the claims, nos.	
		the drawings, sheets/figs	
		any table(s) related to sequence listing (specify):	
*	If it	tem 4 applies, some or all of those sheets may be marked "supers	

International application No.

PCT/JP2005/000238

Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially the not been examined in respect of:
	e entire international application
$\boxtimes$	uims Nos 1-6
because	
	e said international application, or the said claims Nos. <u>1-6</u> ate to the following subject matter which does not require an international preliminary examination ( <i>specify</i> ):
	Claims 1 to 6 pertain to methods for the
	reatment of the human body by means of surgery or
	herapy.
	e description. claims or drawings ( <i>indicate particular elements below</i> ) or said claims Nos. e so unclear that no meaningful opinion could be formed ( <i>specif</i> y):
	e claims, or said claims Nos are so inadequately supported
	o international search report has been established for said claims Nos. 1-6
	e nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative structions in that:
	e written form has not been furnished
	does not comply with the standard
į	e computer readable form has not been furnished
	does not comply with the standard
	e tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the chnical requirements provided for in Annex C-bis of the Administrative Instructions.
	ee Supplemental Box for further details.

International application No.
PCT/JP2005/000238

вох	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1.	Statement			
	Novelty (N)	Claims	7-10	YES
		Claims		NO
	Inventive step (IS)	Claims		YES
		Claims	7-10	NO
	Industrial applicability (IA)	Claims	7-10	YES
		Claims		NO
	•			

2. Citations and explanations (Rule 70.7)

[Citations]

Document 1: JP 07-503455 A (San Diego Regional Cancer Center), 13 April 1995

Document 2: JP 58-157723 A (Ajinomoto Co., Inc.), 19
September 1983

Document 3: Mol. Ther., 2003, Vol. 7, No. 2, pages 210 to 217

Document 4: The Cell, 2001, Vol. 33, No. 6, pages 227 to 231

[Explanations]

### Claims 7 to 10

The invention set forth in claims 7 to 10 is not disclosed in any of the documents that are cited in the international search report; therefore, said invention is novel. However, the invention in question does not involve an inventive step in the light of documents 1 to 4 cited in the international search report.

Document 1 discloses anti-tumor agents that contain tumor antigens and cells that are capable of expressing a

International application No.
PCT/JP2005/000238

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

cytokine gene product such as IL-2, while document 2 discloses anti-tumor agents that contain IL-2.

Meanwhile, gene therapy is a well-known technique for administering a protein as a medicament, and gene therapy techniques that employ a minus-strand RNA virus vector as a gene expression vector are also well known, as disclosed in documents 3 and 4. Such being the case, it would have been obvious to a person skilled in the art to apply a configuration that employs a minus-strand RNA virus vector in order to administer a cytokine such as the protein IL-2 in the anti-tumor agents that are disclosed in documents 1 and 2. Furthermore, it is common practice for a person skilled in the art to confirm whether cytokines such as IL-2 exhibit an anti-tumor effect against each type of tumor.

International application No.

PCT/JP2005/000238

Supplemental Box Relating to Sequence Listing			
Continuation of Box No. I, item 2:			
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention. this report was established on the basis of:			
a. type of material			
a sequence listing			
table(s) related to the sequence listing  b. format of material			
in written format			
in computer readable form			
c. time of filing/furnishing			
contained in the international application as filed			
filed together with the international application in computer readable form			
furnished subsequently to this Authority for the purposes of search and/or examination			
received by this Authority as an amendment* on			
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.			
3. Additional comments:			
* If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."			